BG63048B1 - Цитостатици, модифицирани с въглехидрати - Google Patents

Цитостатици, модифицирани с въглехидрати Download PDF

Info

Publication number
BG63048B1
BG63048B1 BG101892A BG10189297A BG63048B1 BG 63048 B1 BG63048 B1 BG 63048B1 BG 101892 A BG101892 A BG 101892A BG 10189297 A BG10189297 A BG 10189297A BG 63048 B1 BG63048 B1 BG 63048B1
Authority
BG
Bulgaria
Prior art keywords
methanol
mmol
methylene chloride
tlc
methyl
Prior art date
Application number
BG101892A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101892A (en
Inventor
Hans - Georg LERCHEN
Dem Bruch Karsten Von
Uwe Petersen
Joerg Baumgarten
Norbert Piel
Horst-Peter Antonicek
Walter Weichel
Michael Sperzel
Klaus Bremm
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG101892A publication Critical patent/BG101892A/xx
Publication of BG63048B1 publication Critical patent/BG63048B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
BG101892A 1995-04-04 1997-09-16 Цитостатици, модифицирани с въглехидрати BG63048B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19512484A DE19512484A1 (de) 1995-04-04 1995-04-04 Kohlenhydratmodifizierte Cytostatika
PCT/EP1996/001279 WO1996031532A1 (de) 1995-04-04 1996-03-22 Kohlenhydratmodifizierte cytostatika

Publications (2)

Publication Number Publication Date
BG101892A BG101892A (en) 1998-05-29
BG63048B1 true BG63048B1 (bg) 2001-02-28

Family

ID=7758679

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101892A BG63048B1 (bg) 1995-04-04 1997-09-16 Цитостатици, модифицирани с въглехидрати

Country Status (27)

Country Link
US (1) US6271342B1 (es)
EP (1) EP0819135B1 (es)
JP (1) JPH11502860A (es)
KR (1) KR19980703591A (es)
CN (1) CN1185786A (es)
AT (1) ATE186738T1 (es)
AU (1) AU713466B2 (es)
BG (1) BG63048B1 (es)
BR (1) BR9604825A (es)
CA (1) CA2217164A1 (es)
CZ (1) CZ291098B6 (es)
DE (2) DE19512484A1 (es)
DK (1) DK0819135T3 (es)
EE (1) EE03619B1 (es)
ES (1) ES2140078T3 (es)
GR (1) GR3032605T3 (es)
HU (1) HUP9800513A3 (es)
IS (1) IS1822B (es)
MX (1) MX9707613A (es)
NO (1) NO974564L (es)
NZ (1) NZ305855A (es)
PL (1) PL183574B1 (es)
RU (1) RU2170234C2 (es)
SK (1) SK281785B6 (es)
TW (1) TW384290B (es)
UA (1) UA61054C2 (es)
WO (1) WO1996031532A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT934329E (pt) * 1996-09-30 2002-05-31 Bayer Ag Glicoconjugados de derivados de camptotecina modificados (ligacao 20-o)
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
HUP0100051A3 (en) 1997-09-15 2002-08-28 Procter & Gamble Antimicrobial quinolones, their compositions and uses
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US7220824B1 (en) * 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219634A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Cytostatic-glycoconjugates having specifically cleavable peptidic linking units
EP1238678A1 (en) * 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
WO2003040093A2 (de) * 2001-11-09 2003-05-15 Bayer Healthcare Ag Isotopencodierte affinitätsmarker 2
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
NZ547438A (en) 2003-12-19 2010-01-29 Genentech Inc Monovalent antibody fragments useful as therapeutics
CA2647457C (en) 2006-03-28 2011-05-24 The Procter & Gamble Company A hydride reduction process for preparing quinolone intermediates
MX2008012328A (es) 2006-03-28 2008-10-09 Procter & Gamble Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil- piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolinc arboxilico.
KR101084521B1 (ko) 2006-03-28 2011-11-18 워너 칠콧 컴퍼니 엘엘씨 퀴놀론 중간체를 제조하기 위한 커플링 방법
CN107531736B (zh) * 2015-01-06 2022-04-15 免疫疫苗科技公司 脂质a模拟物、其制备方法和用途
LT3380124T (lt) 2015-11-25 2024-06-25 Ligachem Biosciences Inc. Konjugatai, apimantys savaime skaidančias grupes, ir su jais susiję būdai
JP7327899B2 (ja) 2015-11-25 2023-08-16 レゴケム バイオサイエンシズ， インク． 分岐リンカーを含む抗体－薬物複合体及びそれらに関連する方法
US11654197B2 (en) 2017-03-29 2023-05-23 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
CA3099680A1 (en) 2018-05-09 2019-11-14 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5977356A (ja) * 1982-06-30 1984-05-02 Fuji Photo Film Co Ltd 螢光アツセイ用多層分析要素およびそれを用いる螢光アツセイ法
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
DE3889956T2 (de) * 1987-03-26 1994-12-22 Neorx Corp Metall-Radionuklid-markierte Proteine und Glykoproteine zur Diagnose und Therapie.
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5965695A (en) 1990-05-15 1999-10-12 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE4106101A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Fucose-markierte cytostatika
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
ES2137937T3 (es) 1991-11-29 2000-01-01 Hoechst Ag Peptidos con efecto del tipo de insulina.
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
ZA935697B (en) 1992-08-07 1994-03-10 Sankyo Co Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use
US5872207A (en) 1992-09-04 1999-02-16 Sanofi Pharmaceuticals, Inc. N-terminal-marked peptides immobilized on glass beads and method of preparation and method of use thereof
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5576298A (en) 1992-11-30 1996-11-19 Research And Development Institute, Inc. At Montana State University Peptides from pseudomonas syringae possessing broad-spectrum antibiotic activity
SE9300012D0 (sv) 1993-01-05 1993-01-05 Astra Ab New peptides
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
JPH09504522A (ja) * 1993-10-12 1997-05-06 グリコメド・インコーポレイテッド 細胞接着インヒビターの同定に有用なグリコ−ペプチドのライブラリー
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
FR2729668A1 (fr) 1995-01-23 1996-07-26 Adir Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5677286A (en) * 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US6143931A (en) 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays

Also Published As

Publication number Publication date
WO1996031532A1 (de) 1996-10-10
AU5397696A (en) 1996-10-23
CZ314397A3 (cs) 1998-01-14
ES2140078T3 (es) 2000-02-16
IS1822B (is) 2002-10-01
UA61054C2 (en) 2003-11-17
KR19980703591A (ko) 1998-11-05
JPH11502860A (ja) 1999-03-09
IS4562A (is) 1997-09-18
DE59603678D1 (de) 1999-12-23
NO974564D0 (no) 1997-10-02
SK281785B6 (sk) 2001-07-10
CN1185786A (zh) 1998-06-24
RU2170234C2 (ru) 2001-07-10
US6271342B1 (en) 2001-08-07
EE9700258A (et) 1998-04-15
HUP9800513A3 (en) 1998-09-28
PL322681A1 (en) 1998-02-16
BR9604825A (pt) 1999-01-05
BG101892A (en) 1998-05-29
CZ291098B6 (cs) 2002-12-11
DK0819135T3 (da) 2000-05-08
SK134597A3 (en) 1998-05-06
CA2217164A1 (en) 1996-10-10
DE19512484A1 (de) 1996-10-17
EP0819135B1 (de) 1999-11-17
ATE186738T1 (de) 1999-12-15
HUP9800513A2 (hu) 1998-06-29
EE03619B1 (et) 2002-02-15
NO974564L (no) 1997-11-25
AU713466B2 (en) 1999-12-02
NZ305855A (en) 1999-11-29
EP0819135A1 (de) 1998-01-21
MX9707613A (es) 1997-12-31
TW384290B (en) 2000-03-11
PL183574B1 (pl) 2002-06-28
GR3032605T3 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
BG63048B1 (bg) Цитостатици, модифицирани с въглехидрати
EP1447099B1 (de) Antineoplastisch wirkende Polyethylenkonjugate zytostatischer Verbindungen und diese enthaltende Arzneimittel
EP0714903B1 (de) Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
DE69637383T2 (de) Cytotoxinkonjugate umfassend dipeptide
US6156754A (en) Glycoconjugates of modified camptothecin derivatives (A-or B-ring linkage)
EP1619210A1 (en) DDS compounds and method for assaying the same
EA000006B1 (ru) Производные полипирролкарбоксамидонафталина, способ их получения и их применение
DE102009051799B4 (de) Bifunktionale Prodrugs und Drugs
KR20150027217A (ko) 항진균성 항생 암포테리신 b의 n-치환된 제2 세대 유도체, 및 이의 제조 및 응용 방법
SA93130351B1 (ar) مشتقات إندولبيرولوكربازول
HU210744B (en) Process to prepare novel ganglioside derivs. and pharmaceutical compns. contg. them
JP2023515034A (ja) 標的送達及び活性化した免疫刺激性複合体の調製と使用
CA2267328A1 (en) Glycoconjugates from modified camptothecin derivates (20-o-linkage)
EP0599908B1 (en) New ganglioside derivatives
US20020173468A1 (en) Modified cytostatic agents
WO2005026169A1 (en) Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof
WO2001058932A1 (de) Glycokonjugate von cytostatika
IL119334A (en) Carbohydrate modified cytostatics and medicaments containing them
HRP960440A2 (en) Sugar-modified cytostatics
DE10005275A9 (de) Neuartige glycokonjugate
RU2184122C2 (ru) Гликоконъюгаты 20(s)-камптотецина
CZ401799A3 (cs) Glykokonjugáty 20(S)-camptothecinu, způsob jejich výroby, jejich použití a léčiva tyto látky obsahující